About This Deal

Gilead Sciences acquired Pharmasset, Inc. for ~$11.05 billion, a transaction announced in January 2012.

Acquired the hepatitis C drug developer to obtain sofosbuvir (later Sovaldi/Harvoni), transforming Gilead into the leader in HCV cure therapy. Purchased via a $137.00-per-share cash tender offer and merger.

Acquired the hepatitis C drug developer to obtain sofosbuvir (later Sovaldi/Harvoni), transforming Gilead into the leader in HCV cure therapy. Purchased via a $137.00-per-share cash tender offer and merger.

Deal Terms

Acquirer
Gilead Sciences
Target
Pharmasset, Inc.
Value
~$11.05 billion
Date
January 2012
Type
Full acquisition
Status
Completed

Transaction Details

Announced
January 17, 2012

Advisors

Advisory firms were not disclosed for this transaction.

Related Deals & Entities

Sources: Press release ↗

See how Top Bucket AI works for your firm

Request Demo
Top Bucket AI Research

Stay ahead of private markets

Research and market intelligence for private-markets professionals.

✓

You're subscribed.

Thanks for signing up.